Product Code: ETC8846860 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Philippines non-alcoholic steatohepatitis (NASH) market addresses the growing health concerns related to liver diseases caused by the accumulation of fat in the liver. NASH is a progressive form of non-alcoholic fatty liver disease (NAFLD) that can lead to liver cirrhosis and other serious complications. Treatment options for NASH include pharmacological therapies aimed at reducing liver inflammation and fibrosis. The market is growing due to the rising incidence of obesity and metabolic syndrome in the Philippines, along with increasing awareness and better diagnostic capabilities for liver diseases. Advances in medical research and drug development are expected to further boost the market.
The growth of the Philippines Non-alcoholic Steatohepatitis (NASH) Market is fueled by the rising incidence of liver diseases, especially as obesity and metabolic disorders become more prevalent in the population. NASH, which is a progressive liver disease caused by fat accumulation in the liver, is often linked to lifestyle factors. As awareness of the condition increases and diagnosis rates rise, there is a growing demand for pharmaceutical treatments targeting NASH. Moreover, advancements in clinical research and drug development are driving innovation in therapies that can slow disease progression and improve liver function, thus contributing to the markets growth.
The Philippines Non-alcoholic Steatohepatitis (NASH) Market faces significant challenges due to the lack of effective and approved treatment options. Many patients rely on lifestyle modifications rather than pharmacological interventions, limiting market growth. Additionally, the high cost of investigational therapies and limited insurance coverage further restricts patient access. Low awareness and underdiagnosis of NASH, especially in its early stages, create additional barriers for market expansion.
The rising prevalence of liver diseases linked to obesity and unhealthy lifestyles creates strong investment opportunities in the non-alcoholic steatohepatitis (NASH) treatment market. Pharmaceutical companies can focus on developing novel drugs for liver fibrosis and inflammation. Investment in liver health diagnostics, including advanced imaging and biomarker testing, presents additional growth avenues. Healthcare infrastructure developments, such as specialized liver disease clinics and wellness centers, can also attract investment. Collaborations with research institutions to advance treatment options and early disease detection methods will further drive market potential.
The Philippine government addresses liver disease management through healthcare policies and pharmaceutical regulations. The DOH promotes public health initiatives targeting obesity and metabolic disorders, which are major risk factors for NASH. The FDA ensures the safe approval and distribution of NASH drugs, influencing market entry for pharmaceutical companies. PhilHealth coverage for liver disease treatment enhances patient access to care. Additionally, government-backed research initiatives encourage innovation in liver disease diagnostics and therapeutics, supporting industry growth.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Non-alcoholic Steatohepatitis Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Non-alcoholic Steatohepatitis Market - Industry Life Cycle |
3.4 Philippines Non-alcoholic Steatohepatitis Market - Porter's Five Forces |
3.5 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Sales Channel, 2021 & 2031F |
3.7 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Disease Cause, 2021 & 2031F |
3.8 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Philippines Non-alcoholic Steatohepatitis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Non-alcoholic Steatohepatitis Market Trends |
6 Philippines Non-alcoholic Steatohepatitis Market, By Types |
6.1 Philippines Non-alcoholic Steatohepatitis Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Vitamin E and Pioglitazone, 2021- 2031F |
6.1.4 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Ocaliva, 2021- 2031F |
6.1.5 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Elafibranor, 2021- 2031F |
6.1.6 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Selonsertib and Cenicriviroc, 2021- 2031F |
6.1.7 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Obeticholic Acid, 2021- 2031F |
6.1.8 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Philippines Non-alcoholic Steatohepatitis Market, By Sales Channel |
6.2.1 Overview and Analysis |
6.2.2 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.2.3 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Online Providers, 2021- 2031F |
6.2.4 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.3 Philippines Non-alcoholic Steatohepatitis Market, By Disease Cause |
6.3.1 Overview and Analysis |
6.3.2 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hypertension, 2021- 2031F |
6.3.3 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Heart Disease, 2021- 2031F |
6.3.4 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By High Blood Lipid, 2021- 2031F |
6.3.5 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Type 2 Diabetes, 2021- 2031F |
6.3.6 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Obesity, 2021- 2031F |
6.4 Philippines Non-alcoholic Steatohepatitis Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Philippines Non-alcoholic Steatohepatitis Market Revenues & Volume, By Homecare settings, 2021- 2031F |
7 Philippines Non-alcoholic Steatohepatitis Market Import-Export Trade Statistics |
7.1 Philippines Non-alcoholic Steatohepatitis Market Export to Major Countries |
7.2 Philippines Non-alcoholic Steatohepatitis Market Imports from Major Countries |
8 Philippines Non-alcoholic Steatohepatitis Market Key Performance Indicators |
9 Philippines Non-alcoholic Steatohepatitis Market - Opportunity Assessment |
9.1 Philippines Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Philippines Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Sales Channel, 2021 & 2031F |
9.3 Philippines Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Disease Cause, 2021 & 2031F |
9.4 Philippines Non-alcoholic Steatohepatitis Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Philippines Non-alcoholic Steatohepatitis Market - Competitive Landscape |
10.1 Philippines Non-alcoholic Steatohepatitis Market Revenue Share, By Companies, 2024 |
10.2 Philippines Non-alcoholic Steatohepatitis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |